Genta CLL Agent Genasense Has Not Shown Clinical Benefit, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee votes seven to three that data from Genta’s randomized trial of the chronic lymphocytic leukemia therapy does not represent substantial evidence of clinical benefit during Sept. 6 meeting.
You may also be interested in...
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.